David T. Wyatt, MD

Endocrinology and Metabolism            

Titles: Program director, Endocrinology, Children's Hospital of Wisconsin; professor, Pedatrics, Medical College of Wisconsin.

Education: Medical degree, University of Texas Health Science Center at Dallas, 1977; residency, Case Western Reserve Medical School, Cleveland, 1977–1980, chief resident, 1980-1981; fellowship, Washington University, St. Louis, 1981-1984.     

Certifications: Pediatrics, Pediatric Endocrinology.

Honors: Best Doctors in America, 2004.

Research interests: Growth disorders, growth hormone therapy and diabetes.

Representative publications:

• Wyatt DT, Mark D, Slyper AH. A Survey of Growth Hormone Practices by 251 Pediatric Endocrinologists. Journal of Clinical Endocrinology and Metabolism 1995;80:3292-3297.
• Wyatt DT, Gesundheit N, Sherman B. Changes in Thyroid Hormone Levels During Growth Hormone Therapy in Initially Euthyroid Patients—Lack of Need for Thyroxine Supplementation. Journal of Clinical Endocrinology and Metabolism 1998; 83:3493-3497.
• Wyatt DT, Simms M, Horwitz S. Widespread Growth Retardation and Variable Growth Recovery in Foster Children in the First Year after Initial Placement. Archives of Pediatric Adolescent Medicine 1997;151:813-816.
• Wyatt DT. Melanocytic Nevi in Children Treated with Growth Hormone. Pediatrics 1999;104:1045-1049.
• Parker K, Wyatt DT, Blethen S, Babtista J, Price L. Screening Girls with Turner Syndrome: The National Cooperative Growth Study Experience. Journal of Pediatrics 2003:143:133-5.
• Alemzadeh R, Wyatt DT. Diabetes Mellitus (Chapter 583) pp 1947-1972. Nelson Textbook of Pediatrics, 17^th Edition. Behrman RE, Kliegman RM, Jenson HB, editors. Saunders 2003.

Current grants:

• Concentration Control Trial of Norditropin SimpleX in Children with Growth Hormone Deficiency: A 2-year, Open-label, Randomized, Multi-center Trial (Novo Nordisk HGH-2051), Novo Nordisk, principal investigator.
• Norditropin in Children with Growth Failure Associated with IGF Deficiency: A 12-month, Open-label, Randomized, Parallel Group Study (Novo Nordisk HGH-2147), Novo Nordisk, principal investigator.

Contact information: Phone: (414) 266-6750. Fax: (414) 266-6749.